Full Press Release Details
Lexaria Forward Stock Split
KELOWNA, BC-- December 16, 2015 - Lexaria Corp. (OTCQB: LXRPD)
(CNSX: LXX) (the "Company" or "Lexaria") confirms the earlier announced Lexaria
forward stock split has taken place and the company s shares begin trading on a
post-split basis today at the open of trading.
On November 24, 2015, our board of directors approved a forward
stock split of our authorized and issued and outstanding shares of common stock
on a basis of 1 old share of common stock for 1.1 new shares of common stock.
Upon effect of the forward stock split our authorized capital will increase to
220,000,000 shares of common stock, par value $0.001.
The reverse stock split has been reviewed by the Financial
Industry Regulatory Authority ("FINRA") and the Canadian Securities Exchange
("CSE") and has been approved for filing with an effective date of December 16,
2015. The Company s trading symbol on the Canadian Securities Exchange remains
The forward split is effective with the OTC Markets at the
opening of trading on December 16, 2015 under the symbol LXRPD . The "D" will
be placed on our ticker symbol for 20 business days, and then the trading symbol
will revert back to LXRP. Our new CUSIP number is 52886N307.
Lexaria thanks its shareholders for their continued support and
will in the future provide information at an appropriate time if our board of
directors should decide at some point in the future to once again effect a
forward stock split of the company s shares.
Lexaria is a food sciences company, with common shares quoted
in the USA with symbol LXRP and in Canada with symbol LXX. The Company uses
innovative technology to deliver unique food experiences. www.lexarienergy.com
FOR FURTHER INFORMATION PLEASE CONTACT:
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy, products and
services, competitive positions, growth opportunities, plans and objectives of
management for future operations, including statements that include words such
as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may,"
"could," "should," "will," and other similar expressions are forward-looking
statements, including but not limited to: the provision of any significant
investor relations or media relations services. Such forward-looking statements
are estimates reflecting the Company's best judgment based upon current
information and involve a number of risks and uncertainties, and there can be no
assurance that other factors will not affect the accuracy of such
forward-looking statements. Access to capital, or lack thereof, is a major risk
and there is no assurance that the Company will be able to raise required
working capital. Factors which could cause actual results to differ materially
from those estimated by the Company include, but are not limited to, government
regulation, managing and maintaining growth, the effect of adverse publicity,
litigation, competition, the patent application and approval process and other
factors which may be identified from time to time in the Company's public
announcements and filings. There is no assurance that the medical marijuana,
hemp oil sector, or alternative health businesses will provide any benefit to
Lexaria, or that the Company will experience any growth through participation in
these sectors. There is no assurance that existing capital is sufficient for the
Company's needs or that it will not need to attempt to raise additional capital.
There is no assurance that any planned corporate activity, business venture, or
initiative will be pursued, or if pursued, will be successful. There is no
assurance that any hemp oil or cannabinoid-based product will promote, assist,
or maintain any beneficial human health conditions whatsoever. There is no
assurance that the cannabinoid/lipid infusion technology will provide any
increase in bioavailability to any individual person. There is no assurance that
any patent application in the USA or any other nation or under any treaty will
result in the award of an actual patent; nor that an award of any actual patent
will protect against challenges from unknown third parties. There is no
assurance that any of Lexaria s postulated uses, benefits, or advantages for the
patent-pending technology will in fact be realized in any manner or in any part.
No statement herein has been evaluated by the Food and Drug Administration
(FDA). ViPovaTM products and Lexaria Energy products are not intended
to diagnose, treat, cure or prevent any disease.
The CSE has not reviewed
and does not accept responsibility for the adequacy or accuracy of this